566 related articles for article (PubMed ID: 16329145)
21. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
22. Androgen deprivation therapy for prostate cancer: effects on hand function.
Soyupek F; Soyupek S; Perk H; Ozorak A
Urol Oncol; 2008; 26(2):141-6. PubMed ID: 18312932
[TBL] [Abstract][Full Text] [Related]
23. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
Huhtaniemi I; Venho P; Jacobi G; Rannikko S
J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
[TBL] [Abstract][Full Text] [Related]
24. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy.
Morote J; Planas J; Salvador C; Raventós CX; Catalán R; Reventós J
BJU Int; 2009 Feb; 103(3):332-5; discussion 335. PubMed ID: 19007366
[TBL] [Abstract][Full Text] [Related]
25. Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image.
Issa MM; Lendvay TS; Bouet R; Young MR; Petros JA; Marshall FF
J Urol; 2005 Sep; 174(3):893-7. PubMed ID: 16093982
[TBL] [Abstract][Full Text] [Related]
26. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
27. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
28. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
[TBL] [Abstract][Full Text] [Related]
29. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
[TBL] [Abstract][Full Text] [Related]
30. Influence of radical prostatectomy on serum hormone levels.
Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
[TBL] [Abstract][Full Text] [Related]
31. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
St-Arnaud R; Lachance R; Dupont A; Labrie F
Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
[TBL] [Abstract][Full Text] [Related]
32. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.
Greil S; Robinson EA; Singal B; Kleer E
Urology; 2009 Mar; 73(3):631-4. PubMed ID: 19110301
[TBL] [Abstract][Full Text] [Related]
33. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
34. Serum free/total prostatic-specific antigen in prostate cancer patients treated with LH-RH agonists.
Stein A; Barak M; Mecz Y; Rubinov R; Lurie A
Eur Urol; 1997; 32(1):64-8. PubMed ID: 9266234
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
[TBL] [Abstract][Full Text] [Related]
36. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
37. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
38. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
[TBL] [Abstract][Full Text] [Related]
39. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
Penson DF; Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M
J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
[TBL] [Abstract][Full Text] [Related]
40. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
